(CercleFinance.com) – GSK announced on Friday that Jemperli has reached its primary endpoint in a phase III clinical study in the treatment of endometrial cancer.
The UK pharma company says preliminary results show the trial showed ‘significant’ benefit both clinically and statistically in patients with DNA (dMMR) mismatches and the MSI-H phenotype , but also in the general population.
A significant improvement in disease progression-free survival was also observed in patients with DNA mismatches (dMMR) and the MSI-H phenotype, he adds.
As far as overall survival is concerned, the data collected so far are insufficient to draw conclusions, but GSK reports an overall trend that is ‘favourable’ for the time being.
GSK shares rose 0.2% on Friday morning on the London Stock Exchange following this announcement.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
